# Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe

> **NCT02597439** · PHASE4 · COMPLETED · sponsor: **Rene Kahn** · enrollment: 145 (actual)

## Conditions studied

- Ultra High Risk for Psychosis

## Interventions

- **DRUG:** Omega-3 fatty acids
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02597439
- **Lead sponsor:** Rene Kahn
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-30
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-02-01
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02597439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02597439, "Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT02597439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*